Parenteral Manual

Dexrazoxane (NON-FORMULARY)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
ZINECARD
Classification: 
Cardioprotective agent - CYTOTOXIC
Original Date: 
August 2005
Revised Date: 
November 2020
Indications: 
  • To prevent or reduce the incidence and severity of cardiotoxicity of doxorubicin or other anthracyclines

THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.

Reconstitution and Stability: 
  • Prepare in biohazard hood
  • Reconstitute 500 mg vial of powder with 50 mL sterile water for injection and 250 mg vial with 25 mL of sterile water for injection to yield a 10 mg/mL solution
  • Vials are stable for 30 minutes at room temperature or up to 3 hours under refrigeration
  • Further dilution with Lactated Ringer's is required to achieve a final concentration of 1.3 to 3mg/mL.
  • The infusion solution is stable for 1 hour at room temperature or if storage is necessary, up to 4 hours when stored under refrigeration
Compatibility: 

- Solutions Compatible: Lactated Ringer's

- No known compatibilities with other medications

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Direct

NO

IV Intermittent Infusion

Yes,

Usual dilution: 1.3 - 3 mg/mL with Lactated Ringer's

Infusion Time:15 - 30 minutes

IV Continuous Infusion NO
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • Ten times the dose of doxorubicin, i.e. if doxorubicin dose is 30 mg/m2, dexrazoxane dose is 300 mg/m2
  • For other anthracyclines, calculate the equivalent cardiotoxic dose of doxorubicin and multiply by 10 for dexrazoxane dose
  • Dosage may differ according to protocol
  • Dosage in renal dysfunction (CrCl<40 mL/min):  recommended dosage ratio is 5:1 (example:  if doxorubicin dose is 30 mg/ m2,   dexrazoxane dose is 150 mg/m2
Potential hazards of parenteral administration: 
  • Pain at injection site (use central line)
  • Mild myelosuppression
  • NOT A VESICANT

- Treatment of unusual side effects are available through the study chair identified on the front page of the protocol and/or pharmacy

Notes: 
  • Must be given within 30 minutes of anthracyline infusion
  • Cardioprotective effect of dexrazoxane is less with mitoxantrone
  • No known dosage modifications for hepatic insufficiency
References: 

Zinecard Product Monograph. Pfizer Canada. Revised 30 March 2015.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.